Medpace stockholders approve amended incentive plan and elect two directors
At its May 16, 2025 annual meeting, Medpace stockholders approved the Amended 2016 Incentive Award Plan, which extends the plan's expiration date to February 6, 2035 without adding authorized shares. Stockholders also elected August J. Troendle and Dani S. Zander as Class III directors, ratified Deloitte & Touche LLP as auditor for 2025, and approved an advisory say-on-pay vote and a non-binding simple majority voting proposal.
Key points
- Amended 2016 Plan extends expiration to February 6, 2035 and does not increase authorized shares; approved 25,567,981 for, 702,406 against
- Troendle received 21,156,998 votes for and 5,128,383 withheld; Zander received 25,858,694 for and 426,687 withheld
- Advisory say-on-pay approved with 24,918,234 for and 1,340,033 against
- Non-binding simple majority voting proposal approved with 18,210,462 for and 8,021,457 against
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 16, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.